CD70 in Thymic Squamous Cell Carcinoma: Potential Diagnostic Markers and Immunotherapeutic Targets
CD70 – a ligand protein of CD27 on lymphocytes – is expressed in a large spectrum of malignancies. It is an attractive target for antibody-based therapy and several clinical trials are currently being conducted. However, there is no evidence regarding the expression of CD70 and its relationship with...
Main Authors: | Jumpei Kashima, Tsunekazu Hishima, Yusuke Okuma, Hirotoshi Horio, Masumi Ogawa, Yukiko Hayashi, Shin-ichiro Horiguchi, Toru Motoi, Tetsuo Ushiku, Masashi Fukayama |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-01-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.808396/full |
Similar Items
-
Brief Report: High Levels of CD47 Expression in Thymic Epithelial Tumors
by: Thomas Yang Sun, MD, MHS, et al.
Published: (2023-04-01) -
Cisplatin and Irinotecan as First-Line Chemotherapy for Previously Untreated Metastatic Thymic Carcinoma: Updated Analysis
by: Akito Fukuda, et al.
Published: (2022-01-01) -
Immunologic Significance of CD80/CD86 or Major Histocompatibility Complex-II Expression in Thymic Epithelial Tumors
by: Hideki Ikeda, MD, et al.
Published: (2023-10-01) -
Thymic changes as a contributing factor in the increased susceptibility of old Albino Oxford rats to EAE development
by: Marija Petrušić, et al.
Published: (2023-01-01) -
Loss of thymic function promotes EAE relapse in anti-CD52-treated mice
by: Adeolu O. Adegoke, et al.
Published: (2022-01-01)